A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis
Status:
Recruiting
Trial end date:
2023-02-10
Target enrollment:
Participant gender:
Summary
This prospective, interventional, controlled study is aimed to evaluate the efficacy and
safety of cyclophosphamide in the treatment of idiopathic retroperitoneal fibrosis, which
refers to the chronic nonspecific inflammation of retroperitoneal fascia and adipose tissue
that gradually evolves into fibroproliferative disease.